NLM Digital Collections

Search

Start Over Subjects United States ✖Remove constraint Subjects: United States Publication Year 2017 ✖Remove constraint Publication Year: <span class="single" data-blrl-single="2017">2017</span>

171. Medicaid demonstrations: federal action needed to improve oversight of spending : report to the Chairman, Committee on Finance, U.S. Senate

Publication:
Washington, D.C. : U.S. Government Accountability Office, 2017
Subject(s):
Health Expenditures
Medicaid -- economics
Pilot Projects
Cost Control
Federal Government
Government Regulation
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

172. Medicare advantage: CMS should use data on disenrollment and beneficiary health status to strengthen oversight : report to Congressional Requesters

Publication:
Washington, D.C. : U.S. Government Accountability Office, April 2017
Subject(s):
Health Status
Insurance Selection Bias
Medicare Part C -- statistics & numerical data
Government Regulation
Risk
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

173. Veterans crisis line: further efforts needed to improve service : statement for the record for the Committee on Veterans' Affairs, House of Representatives

Publication:
Washington, D.C. : U.S. Government Accountability Office, April 4, 2017
Subject(s):
Health Services Accessibility
Hotlines
Veterans Health
Waiting Lists
Mental Disorders
Time Factors
Veterans
Humans
United States
United States. Department of Veterans Affairs.

174. Medicaid personal care services: more harmonized program requirements and better data are needed : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

Publication:
Washington, D.C. : U.S. Government Accountability Office, May 2, 2017
Subject(s):
Fraud -- prevention & control
Community Health Services -- economics
Home Care Services -- economics
Insurance, Health, Reimbursement
Medicaid -- economics
Community Health Services -- organization & administration
Data Collection
Government Regulation
Health Expenditures
Home Care Services -- organization & administration
Quality Assurance, Health Care
State Government
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

175. Emerging infectious diseases: actions needed to ensure improved response to Zika virus disease outbreaks : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

Publication:
Washington, D.C. : U.S. Government Accountability Office, May 23, 2017
Subject(s):
Disease Outbreaks -- prevention & control
Mosquito Control
Zika Virus Infection -- epidemiology
Zika Virus Infection -- prevention & control
Zika Virus Infection -- transmission
Federal Government
State Government
Zika Virus Infection -- diagnosis
Humans
United States
United States. Food and Drug Administration.
Centers for Disease Control and Prevention (U.S.)

176. Veterans Affairs: improper payment estimates and ongoing efforts for reduction : testimony before the Subcommittee on Oversight and Investigations, Committee on Veterans' Affairs, House of Representatives

Publication:
Washington, D.C. : U.S. Government Accountability Office, May 24, 2017
Subject(s):
Fraud -- prevention & control
Insurance, Disability
Insurance, Health, Reimbursement
Veterans Disability Claims
Veterans Health
Quality Assurance, Health Care
Humans
United States
United States. Department of Veterans Affairs.

177. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 8 (R1) : sterility test general chapter

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, September 2017
Subject(s):
Chemistry, Pharmaceutical -- standards
Drug Approval
Pharmacopoeias as Topic -- standards
Sterilization
Congresses as Topic
International Cooperation
Humans
Europe
Japan
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

178. Preliminary analysis of legislation that would replace subsidies for health care with block grants

Publication:
Washington, D.C. : Congressional Budget Office, September 2017
Subject(s):
Budgets -- legislation & jurisprudence
Budgets -- statistics & numerical data
Budgets -- trends
Financing, Government -- legislation & jurisprudence
Insurance Coverage -- economics
Insurance Coverage -- legislation & jurisprudence
Insurance Coverage -- trends
Insurance, Health -- economics
Insurance, Health -- legislation & jurisprudence
Insurance, Health -- trends
Federal Government
Forecasting
Health Insurance Exchanges -- economics
Health Insurance Exchanges -- legislation & jurisprudence
Health Insurance Exchanges -- trends
Insurance, Major Medical -- economics
Insurance, Major Medical -- trends
Medicaid -- economics
Medicaid -- legislation & jurisprudence
Medically Uninsured -- legislation & jurisprudence
Medically Uninsured -- statistics & numerical data
State Government
Taxes
Humans
United States
United States.

179. Disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis: effectiveness and value : final evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, March 6, 2017
Subject(s):
Comparative Effectiveness Research
Multiple Sclerosis, Chronic Progressive -- drug therapy
Multiple Sclerosis, Relapsing-Remitting -- drug therapy
Antirheumatic Agents -- adverse effects
Antirheumatic Agents -- economics
Antirheumatic Agents -- therapeutic use
Benchmarking
Cost-Benefit Analysis
Immunosuppressive Agents -- adverse effects
Immunosuppressive Agents -- economics
Immunosuppressive Agents -- therapeutic use
Insurance Coverage
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

180. Targeted immune modulators for rheumatoid arthritis: effectiveness & value : evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, March 10, 2017
Subject(s):
Arthritis, Rheumatoid -- drug therapy
Comparative Effectiveness Research
Immunologic Factors -- therapeutic use
Abatacept -- therapeutic use
Adalimumab -- therapeutic use
Certolizumab Pegol -- therapeutic use
Cost-Benefit Analysis
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Immunotherapy
Infliximab -- therapeutic use
Interleukin-6 -- antagonists & inhibitors
Protein Kinase Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Rituximab -- therapeutic use
Treatment Outcome
Tumor Necrosis Factor-alpha -- antagonists & inhibitors
Value-Based Purchasing
Humans
United States